Loading organizations...
Doron Therapeutics is a clinical-stage biotechnology company developing placental-derived biologic drugs for osteoarthritis, based in Chapel Hill, North Carolina. The organization focuses on orthopedics and degenerative musculoskeletal conditions, specifically advancing its lead product, MOTYS, a Phase 3-ready intra-articular injectable designed to deliver anti-inflammatory, tissue-protective, and regenerative growth factors to treat knee osteoarthritis. Operating with fewer than 10 employees, the startup recently secured $11 million in Series A venture funding to progress its late-stage clinical trials. The enterprise operates as a management-led spinout from Bioventus Inc., which currently serves as the licensor for its primary asset and retains a minority shareholder position. Its board of directors now includes prominent industry figures such as Karen Zaderej, the former chief executive officer of Axogen Inc. Doron Therapeutics was originally founded in February 2023 by chief executive officer Alessandra Pavesio.
Doron Therapeutics has raised $11.0M across 1 funding round.
Doron Therapeutics has raised $11.0M in total across 1 funding round.
Doron Therapeutics has raised $11.0M in total across 1 funding round.
Doron Therapeutics's investors include SPRIM Global Investments.
Doron Therapeutics has raised $11.0M across 1 funding round. Most recently, it raised $11.0M Series A in November 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 27, 2024 | $11M Series A | Sprim Global Investments | — | Announced |
